“Megan’s leadership has been a significant driver of Praxis’s success to date,” said Mr. Souza. “As COO, she is uniquely positioned to guide Praxis through its next phase, driving disciplined ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Praxis Precision Medicines (PRAX) has drawn investor attention after recent share price moves, with the stock showing sharply different returns over the past year compared with its performance over ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities are serving as joint book-running managers for the ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

Praxis Precision Medicines has recorded a midphase win in epilepsy, linking the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the ...

Praxis Precision Medicines’ challenge to Sage Therapeutics has unraveled. With a phase 2/3 clinical trial in major depressive disorder (MDD) failing comprehensively, Praxis is stopping work on a ...

As of Monday, December 29, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 15.27%, which has investors ...

In December 2025, Praxis announced the successful completion of its pre-NDA meeting with the FDA, including the receipt of written feedback and an in-person meeting. The Company has aligned with the ...